Kopp Family Office LLC Sells 17,800 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Kopp Family Office LLC reduced its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 1.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 926,975 shares of the medical research company’s stock after selling 17,800 shares during the quarter. NeoGenomics makes up approximately 8.8% of Kopp Family Office LLC’s holdings, making the stock its 4th largest holding. Kopp Family Office LLC owned about 0.72% of NeoGenomics worth $13,673,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Geode Capital Management LLC lifted its position in shares of NeoGenomics by 1.2% during the third quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company’s stock worth $45,022,000 after purchasing an additional 36,136 shares in the last quarter. Jennison Associates LLC lifted its holdings in NeoGenomics by 4.7% during the 3rd quarter. Jennison Associates LLC now owns 1,276,468 shares of the medical research company’s stock worth $18,828,000 after buying an additional 57,041 shares in the last quarter. First Light Asset Management LLC boosted its position in NeoGenomics by 14.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock valued at $52,464,000 after buying an additional 480,396 shares during the last quarter. Blue Trust Inc. raised its position in shares of NeoGenomics by 42.3% during the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after acquiring an additional 987 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in NeoGenomics by 152.6% in the second quarter. Sei Investments Co. now owns 263,761 shares of the medical research company’s stock valued at $3,658,000 after acquiring an additional 159,350 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors.

Insider Activity

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of NeoGenomics stock in a transaction on Friday, November 15th. The stock was sold at an average price of $15.36, for a total transaction of $79,488.00. Following the completion of the sale, the general counsel now owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. This trade represents a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.30% of the company’s stock.

NeoGenomics Trading Down 2.3 %

NASDAQ NEO traded down $0.39 on Tuesday, hitting $16.53. The company’s stock had a trading volume of 103,074 shares, compared to its average volume of 798,937. The company’s 50-day moving average is $16.14 and its 200 day moving average is $15.42. The firm has a market cap of $2.12 billion, a PE ratio of -27.10 and a beta of 1.24. NeoGenomics, Inc. has a 1-year low of $12.77 and a 1-year high of $19.00. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The business had revenue of $167.80 million for the quarter, compared to analysts’ expectations of $167.00 million. During the same quarter in the prior year, the firm posted ($0.06) earnings per share. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. As a group, analysts predict that NeoGenomics, Inc. will post -0.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target on the stock. Benchmark reaffirmed a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a research note on Tuesday, September 24th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a research note on Wednesday, November 6th. Finally, Bank of America lifted their price objective on NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $20.30.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.